5 Swedish universities found, MTH1 activity is necessary to change the cell survival, which is essential for cancer cell survival molecule. They identified the isolated enzyme inhibitor, for the treatment of cancer using these molecules.
In recent decades, the development of new anti-cancer drugs will focus on the specific targeting of cancer cells in a genetic defect. These drugs are often at first onset, but soon there will be resistance.Now, from the Karolinska Institute and the leading life science laboratories, researchers from five universities in Sweden consists of a team of researchers found that all of the tests for cancer are dependent on a common activity, and this activity seems to be independent of the presence of cancer specific genetic alteration. The research team confirmed that all cancer studies are needed MTH1 enzymes to survive. In this regard, different from normal cancer cells, which without this enzyme.
The person in charge of the study, Karolinska Institute Professor Thomas Helleday said: “The new concept is based metabolic changes in cancer cells, resulting in oxidation of the nucleotide components based on MTH1 cleared oxide components to prevent this oxidation. Stress incorporation into DNA, the DNA becomes damaged, which ensures that replication of cancer cells, so that they can be performed to divide and proliferate. MTH1 using an enzyme inhibitor may be blocked, damaged nucleotides into the DNA damage can thus killing the cancer cells. normal cells do not need MTH1, their nucleotide components to prevent damage by regulating metabolism. cancer cells need to survive alone find a common activity for the treatment of cancer has opened up a whole new ways. ”
In order to promote the concept to the clinical application of this treatment, the scientists and researchers from five universities in Sweden launched a multi-disciplinary cooperation. They generate a powerful inhibitor MTH1 proved capable of selectively killing tumor surgical resection of skin cancer in the cancer cells.
Sahlgrenska University Hospital surgeon, Dr. Roger Olofsson Bagge Sahlgrenska Academy of Gothenburg University, said: “When we see a tumor from melanoma patients resistant to all current treatment responded well to this treatment, we are very happy You rarely have the opportunity to experience and witness such a breakthrough. ”
But Thomas Helleday said that before the clinical trials as well as a lot of work to be done, which could take at least one or two years. Published in the journal Nature in another article, the part of the members of the research team in Sweden with some collaborators from Austria and the United Kingdom along with the results of several studies presented, confirming the past, some even kill cancer cells but also by substances identified inhibition MTH1 enzymes work, but now people realize this.
“Some of the existing anti-cancer drugs hit the MTH1, suggesting that this concept really works and now we understand this mechanism, we can develop a very selective inhibitors,” Thomas Helleday said.